← Back to Clinical Trials
RecruitingNCT07420803

A Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionChronic Dizziness
SponsorMayo Clinic
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment60
SexALL
Min Age18 Years
Max AgeN/A
Start Date2026-03
Completion2027-03
Interventions
Sham DeviceAuricular transcutaneous vagus nerve stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with aurical transcutaneous vagus nerve stimulation (aTVNS).

Eligibility Criteria

Inclusion Criteria: * Age 18-75, PPPD diagnosis per ICVD. * Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in. * On stable medications/therapy for ≥4 weeks prior to baseline (if any). Exclusion Criteria: * Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia. * Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (\>1 in past 12 months). * Neck surgery, vagotomy, or any condition interfering with vagal stimulation. * Pregnancy.

Related Trials